With regard to the Ras/p38-MAPK pathway role downstream of both TGF-β and IL-6 [94], blocking the Ras signaling pathway may represent a novel approach to controlling both the TGF-β pathway and the inflammatory pathway in SSc [88]. This evidence concerns the gene IL6 and systemic sclerosis.